iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy

iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy

Abstract Background HIV therapeutic vaccination aims to improve the immune responses against HIV in order to control viral replication without the need for combined antiretroviral therapy (cART). iHIVARNA-01 is a novel vaccine combining mRNA delivery and T-cell immunogen (HTI) based on conserved tar...

Full description

Bibliographic Details
Main Authors: Wesley de Jong, Joeri Aerts, Sabine Allard, Christian Brander, Jozefien Buyze, Eric Florence, Eric van Gorp, Guido Vanham, Lorna Leal, Beatriz Mothe, Kris Thielemans, Montse Plana, Félipe Garcia, Rob Gruters, on behalf of the iHIVARNA consortium
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Trials
Subjects:
HIV-1
Therapeutic vaccine
Functional cure
Immunotherapy
Reservoir
Lymph node
Online Access:http://link.springer.com/article/10.1186/s13063-019-3409-1

Internet

http://link.springer.com/article/10.1186/s13063-019-3409-1

Similar Items